nSMOL for fast and precise mAb Bioanalysis
Shimadzu’s new nSMOL Antibody BA reagent kit offers a unique and standardized workflow for the quantitation of monoclonal antibody drugs by LC-MS/MS in blood or other biological samples. The technique, called nano-Surface and Molecular-Orientation Limited (nSMOL) proteolysis, has been designed to minimize sample complexity while maintaining the specificity of the protein substrate for LC–MS/MS quantitation in therapeutic drug monitoring of mAbs. nSMOL proteolysis is an entirely novel solid-solid proteolysis method engineered to deliver highly efficient and quantitative detection of CDR peptides while decreasing the peptide numbers of the analytical target without antibody denaturation.
For more information on Shimadzu’s total solution for biopharmaceutical lab please visit:
www.shimadzu.eu/nsmol-antibody-ba-kit and https://www.youtube.com/watch?v=KoOarzAQg68
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
